Skip to content
Caplin Point Laboratories logo

Caplin Point Laboratories

CAPLIPOINT NSE
₹2,029.10 −55.50 (−2.66%)
Market Cap
₹15,424 Cr
P/E
22.39
View as Markdown
MCP
Close 20 Nov 2026 ₹2,029.10 1Y +109.90 +5.73%
Start ₹1,919.20

Key Fundamentals

SmallcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
24.20%
Debt to Equity
0.00
EPS (TTM)
₹90.64
Book Value
₹513.34
Market Cap
₹15,424 Cr
P/E (TTM)
22.39
P/B
3.95
ROE
20.90%
Dividend Yield
0.38%
EBITDA
₹876 Cr
52W High
₹2,990.00
52W Low
₹1,500.30
Day Range
₹2,020.00 – ₹2,126.00
Volume
1,65,087

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

Caplin Point Laboratories peer comparison
1,884.9041.254,52,2515.070.85%16.00%20.50%61,63110,987
11,180.5088.262,96,80716.490.27%16.50%22.00%12,1913,363
4,689.5077.801,78,3749.710.82%27.40%15.20%17,4002,099
2,294.6092.521,23,98020.450.04%18.30%17.80%7,8231,332
1,200.0028.631,19,7004.300.08%21.20%21.10%30,3784,303
1,390.2041.441,16,0372.990.57%11.20%13.00%33,0972,760
1,415.0039.451,14,3123.230.92%11.60%15.50%28,1392,855
2,029.1022.3915,4243.950.38%20.90%24.20%2,383700
Median 8 companies1,957.0041.351,21,8404.690.48%17.40%19.15%22,7702,808

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

59 Good

Data confidence 100/100

Category scores

Quality
65
Good
Returns, margins, earnings quality 22% weight
Valuation
72
Strong
Cheap vs sector & own history 24% weight
Growth
51
Average
Sales & profit trajectory 9% weight
Financial Health
81
Strong
Solvency, leverage, coverage 9% weight
Momentum
30
Poor
Trend strength, vol-adjusted 12% weight
Ownership
43
Weak
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

4
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 21.4% CAGR over last 5 years
  • Company's median sales growth is 19.9% of last 10 years

No weaknesses listed

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1225
OscillatorsStrong Bullish225
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
26.74
Bullish
MACD (12,26,9)
−83.89
Bearish
SMA (50)
2,480.50
Bearish
SMA (200)
2,203.61
Bearish

As of

Analyst Rating

Based on 2 analysts
BUY100%

2 of 2 analysts rate Buy, 0 Hold, 0 Sell.

As of

BUY
2
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10YIrregular period
5Y+15.57%
3Y+14.24%
1Y+12.91%
TTM+16.87%

Net profit

Net profit growth by window
10YIrregular period
5Y+20.96%
3Y+19.91%
1Y+20.15%
TTM+17.45%

Operating cash flow

Operating cash flow growth by window
10YIrregular period
5Y+14.22%
3Y+24.50%
1Y+21.06%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10YIrregular period
5Y+3.97 pp
3Y+4.85 pp
1Y+1.37 pp
TTM+0.65 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹402 Cr
Mar 2018₹540 Cr
Mar 2019₹649 Cr
Mar 2020₹863 Cr
Mar 2021₹1,061 Cr
Mar 2022₹1,269 Cr
Mar 2023₹1,467 Cr
Mar 2024₹1,694 Cr
Mar 2025₹1,937 Cr
Mar 2026₹2,187 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹96.00 Cr
Mar 2018₹145 Cr
Mar 2019₹177 Cr
Mar 2020₹215 Cr
Mar 2021₹251 Cr
Mar 2022₹308 Cr
Mar 2023₹377 Cr
Mar 2024₹461 Cr
Mar 2025₹541 Cr
Mar 2026₹650 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹863 Cr −1.5% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 19 Nov 2026
AI opinion · based on fundamentals
Risk medium

Caplin Point Laboratories trades at a PE of 23x with an EPS of ₹90.64 as of 2026-11-19, backed by a 10-year compounded profit growth of 30% and a near debt-free balance sheet (debt-to-equity of 0.07). The stock sits about 30% below its 52-week high of ₹2,990, with a market cap of ₹15,845 Cr and ROE of 17.89%.

Bull Case 7
  • Virtually debt-free with a debt-to-equity ratio of just 0.07, giving the company significant financial flexibility and resilience through business cycles.
  • Exceptional long-term profit compounding at 30% CAGR over 10 years, indicating a durable and scalable business model.
  • Compounded sales growth of 25% over 10 years and a median sales growth of 19.9% over the last decade point to consistent top-line expansion.
  • ROCE of 21.96% reflects efficient capital deployment, well above the cost of capital for most Indian pharmaceutical companies.
  • 10-year average ROE of 25% demonstrates sustained ability to generate strong returns on shareholders' equity over a long period.
  • 5-year compounded profit growth of 21% outpaces the 5-year sales CAGR of 16%, suggesting improving margins or operating leverage.
  • TTM sales growth of 17% is an acceleration from the 3-year CAGR of 14%, suggesting recent momentum in revenue generation.
Bear Case 7
  • Dividend yield of only 0.38% offers minimal income return to shareholders, indicating limited near-term cash distribution.
  • Price-to-book of 4.06x is elevated, meaning the market is pricing in significant future growth that must be delivered to justify the premium.
  • TTM profit growth of 17% has decelerated meaningfully from the 10-year CAGR of 30% and 5-year CAGR of 21%, signalling a potential growth slowdown.
  • Last year ROE of 21% and current ROE of 17.89% show a declining trend from the 10-year average of 25%, indicating diminishing return efficiency.
  • The stock has fallen about 30% from its 52-week high of ₹2,990 to ₹2,084.6, reflecting recent negative sentiment or earnings concern among market participants.
  • With a market cap of ₹15,845 Cr, the company is a mid-cap that can be subject to higher volatility and lower liquidity compared to large-cap pharma peers.
  • The 1-year stock CAGR of 8% significantly trails the 5-year CAGR of 20%, indicating near-term underperformance relative to its own historical trend.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

22h ago

TL;DR: Caplin Point Labs is laying out an ambitious growth roadmap centered on doubling its US business in FY27 and expanding PAT margins toward 25-26%. The COL-II facility expected by August 2027 adds a visible medium-term revenue driver. No material headwinds surfaced in this update cycle. The trend is constructive, with execution on US growth and facility timelines being the key variables to watch.

Positives 3
  • US business to double FY27 Nov 19

    CSU (US business) revenue and profit are anticipated to double in FY27, with the company targeting 20-25% growth in the U.S. market.

  • COL-II facility by Aug 2027 Nov 19

    COL-II facility completion is expected by August 2027, positioned to drive incremental revenue in FY28-29.

  • PAT margin expansion target Nov 19

    Company targets 20-21% PAT margins currently with a goal of reaching 25-26% over time.

Neutral 1
  • FY27 growth guidance outlined Nov 19

    Caplin Point Labs laid out its FY27 roadmap including US growth targets of 20-25%, margin goals, and facility timelines without any immediate catalysts.

Quarterly Results

₹ Cr
CAPLIPOINT quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
410
436
453
459
483
493
502
510
534
543
600
610
630
Expenses
273
293
308
307
318
331
334
332
345
353
396
397
407
Operating Profit
137
142
145
152
165
162
168
178
189
190
204
213
223
OPM %
34%
33%
32%
33%
34%
33%
33%
35%
35%
35%
34%
35%
35%
Other Income
20.43
17
17
19
21
31
26
23
30
34
28
34
33.29
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0.22
Depreciation
12
14
16
16
17
16
17
16
18
19
19
22
23.49
PBT
146
145
146
154
169
177
177
184
201
204
213
225
233
Tax %
20%
18%
17%
19%
22%
21%
18%
18%
20%
19%
19%
20%
22%
Net Profit
116
120
121
125
131
140
145
151
160
166
173
179
182
EPS (₹)
15.13
15.43
16.01
16.31
17.21
18.28
18.76
20.10
20.32
21.56
22.38
23.27
23.43
YoY Sales growth
14
17
16
16
18
13
11
11
11
10
19
20
18

Profit & Loss

₹ Cr
CAPLIPOINT profit and loss, annual, ₹ crore
Particulars Jun 2015Mar 2016 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
252
239
402
540
649
863
1,061
1,269
1,467
1,694
1,937
2,187
2,383
Expenses
192
175
276
345
417
603
732
874
1,025
1,142
1,287
1,422
1,553
Operating Profit
60
64
125
195
232
260
329
395
442
552
651
765
831
OPM %
24%
27%
31%
36%
36%
30%
31%
31%
30%
33%
34%
35%
35%
Other Income
3
4
10
13
19
41
23.54
38.75
55.98
66.94
92
111
129
Interest
1
0
1
0.06
1
0
2
1
1
1
1
1
1
Depreciation
8
7
13
19
23
32
37
47
45
53
66
73
83
PBT
53
60
121
188
227
269
314
386
451
564
677
803
875
Tax %
23%
24%
21%
23%
22%
20%
20%
20%
16%
18%
20%
19%
—
Net Profit
41
46
96
145
177
215
251
308
377
461
541
650
700
EPS (₹)
5.43
6.05
12.65
19.15
23.35
28.42
32.03
39.56
49.57
60.19
70.56
84.36
90.64
Div. Payout %
18%
20%
12%
10%
9%
9%
9%
10%
9%
8%
8%
9%
—
Sales growth
45
38
68
34
20
33
23
20
16
16
14
13
17

Balance Sheet

₹ Cr
CAPLIPOINT balance sheet, annual, ₹ crore
Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
15
15
15
15
15
15
15
15
15
15
15
15
15
Reserves
78
113
210
349
582
858
954
1,252
1,649
2,084
2,619
3,355
3,887
Borrowings
2
2
1
1
36
113
235
219
222
219
222
221
5
Other Liabilities
134
137
133
136
109
139
159
250
305
380
352
446
468
Total Liabilities
229
267
358
500
743
1,126
1,364
1,736
2,191
2,698
3,208
4,038
4,375
Fixed Assets
113
144
152
169
227
272
305
287
280
453
546
580
710
CWIP
31
0
3
15
10
20
14
18
221
117
144
234
215
Investments
0
0
17
47
70
61
11
89
281
376
590
859
966
Other Assets
85
122
186
269
436
772
1,033
1,343
1,410
1,753
1,928
2,365
2,484
Total Assets
229
267
358
500
743
1,126
1,364
1,736
2,191
2,698
3,208
4,038
4,375

Cash Flow

₹ Cr
CAPLIPOINT cash flow, annual, ₹ crore
Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
50
42
68
66
83
45
269
337
271
318
432
523
Investing
−23
−6
−36
−69
−100
−54
−30
−377
−216
−319
−333
−582
Financing
−9
−14
−7
−12
90
80
−24
−41
−28
−38
−38
−46
Net Cash Flow
19
23
25
−14
73
70
215
−81
27
−39
61
−105
Free Cash Flow
24
34
43
18
18
−32
195
246
78
173
241
275
CFO/EBITDA
103
92
73
53
54
38
102
106
81
77
86
87

Ratios

CAPLIPOINT financial ratios, annual
Particulars Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
8
12
30
85
90
97
96
91
98
117
119
138
Inventory Days
37
57
44
44
47
210
139
149
159
183
159
181
Days Payable
112
168
155
144
76
57
68
102
84
116
103
125
Cash Conversion Cycle
−67
−99
−81
−16
61
251
166
138
173
184
175
194
Working Capital Days
−128
−114
−29
47
104
167
145
165
144
166
174
199
ROCE %
68%
62%
68%
63%
45%
33%
28%
28%
26%
26%
26%
24%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Caplin Point Laboratories insights

72 extracted metrics across FY12–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 70.57%
  • Public 14.94%
  • Others 6.56%
  • FIIs 5.73%
  • DIIs 2.20%

No promoter shares pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Caplin Point Laboratories

What does Caplin Point Laboratories Ltd do?
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.
Where is Caplin Point Laboratories Ltd (CAPLIPOINT) listed?
Caplin Point Laboratories Ltd trades as CAPLIPOINT on the NSE and under code 524742 on the BSE.
Which sector does Caplin Point Laboratories Ltd belong to?
Caplin Point Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd has a market capitalisation of ₹15,424 Cr as of 20 Nov 2026, which places it in the Smallcap band.
What is the PE ratio of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd trades at a PE ratio of 22.39 as of 20 Nov 2026, on earnings per share of ₹90.64, against a book value of ₹513.34 per share.
What is the 52-week high and low of Caplin Point Laboratories Ltd?
Over the last 52 weeks Caplin Point Laboratories Ltd has traded between ₹1,500.3 and ₹2,990 as of 20 Nov 2026.
Does Caplin Point Laboratories Ltd pay dividends?
Caplin Point Laboratories Ltd has a dividend yield of 0.38%.
What is the Return on Equity (ROE) of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd reported a return on equity of 20.90%. Its debt-to-equity ratio is 0.00.

Company Information

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.

CEO Dr. Sridhar Ganesan
Employees 3,966
Listed 16 Nov 1994
Face Value ₹2
Shares Outstanding 7,60,11,696

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CAPLIPOINT.md for Caplin Point Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More